Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-02-25

FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc., to support an expanded labeling or indicati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Entyvio (vedolizumab)

Snippet

SUPPL AP for ENTYVIO (VEDOLIZUMAB)